Per determinare se la pressione sanguigna ambulatoriale è più predittiva dell’ipertrofia ventricolare sinistra rispetto alla pressione sanguigna occasionale nei bambini ipertesi, sono stati analizzati i dati ecocardiografici e della pressione sanguigna ambulatoriale di 37 bambini ipertesi non trattati. La massa ventricolare sinistra è stata calcolata utilizzando l’equazione di Devereux, l’indice di massa ventricolare sinistro è stato calcolato come massa ventricolare sinistra (in grammi) / altezza (2,7) (in metri) e l’ipertrofia ventricolare sinistra è stata definita come indice di massa ventricolare sinistro> 51 g / m (2.7).
Sono stati calcolati la pressione sanguigna media, il carico di pressione sanguigna e l’indice di pressione sanguigna (pressione sanguigna media divisa per la pressione sanguigna ambulatoriale pediatrica 95 ° percentile). L’indice di massa ventricolare sinistro era fortemente correlato con l’indice della pressione arteriosa sistolica nelle 24 ore (r = 0,43, P = 0,008) ed era anche correlato con la pressione arteriosa sistolica nelle 24 ore (r = 0,34, P = 0,037), sangue sistolico nelle 24 ore carico di pressione (r = 0,38, P = 0,020), carico di pressione sanguigna sistolica sveglia (r = 0,37, P = 0,025), pressione sanguigna sistolica del sonno (r = 0,33, P = 0,048) e carico di pressione sanguigna sistolica del sonno (r = 0,38, P = 0,021).
L’indice di massa ventricolare sinistro non era correlato all’età, al peso, alla pressione sanguigna clinica o alla pressione sanguigna diastolica ambulatoriale. La prevalenza complessiva dell’ipertrofia ventricolare sinistra è stata del 27%. La prevalenza dell’ipertrofia ventricolare sinistra era del 47% (8 su 17) nei pazienti con carico della pressione arteriosa sistolica> 50% e indice della pressione arteriosa sistolica nelle 24 ore> 1,0, rispetto al 10% (2 su 20) nei pazienti senza entrambi i criteri (P = 0,015). Questi dati suggeriscono che il monitoraggio ambulatoriale della pressione arteriosa può essere utile per la valutazione clinica dei bambini ipertesi, identificando quelli ad alto rischio per la presenza di lesioni d’organo.
Un sistema di punteggio clinico per la selezione dei pazienti per il test di mutazione PTEN viene proposto sulla base di uno studio prospettico di 3042 probandi.
La sindrome di Cowden (CS) e la sindrome di Bannayan-Riley-Ruvalcaba sono alleliche, definite da mutazioni germinali di PTEN e collettivamente denominate sindrome tumorale da amartoma PTEN. Ad oggi, non ci sono criteri esistenti basati su ampie coorti di pazienti potenziali per selezionare i pazienti per il test di mutazione PTEN. Per affrontare questi problemi, abbiamo condotto uno studio prospettico multicentrico in cui sono stati accumulati 3042 probandi che soddisfacevano i criteri clinici rilassati della CS. La scansione della mutazione PTEN, inclusa l’analisi del promotore e dell’ampia delezione, è stata eseguita per tutti i soggetti.
Mutazioni patogene sono state identificate in 290 individui (9,5%). Per valutare il fenotipo clinico e il genotipo PTEN rispetto all’espressione proteica, abbiamo eseguito immunoblotting (PTEN, P-AKT1, P-MAPK1 / 2) per un sottogruppo di pazienti (n = 423). Al fine di ottenere una stima personalizzata della probabilità pretest di mutazione germinale PTEN, abbiamo sviluppato un modello di pratica clinica ottimizzato per identificare pazienti adulti e pediatrici. Per gli adulti, un punteggio semiquantitativo, il punteggio della Cleveland Clinic (CC), ha prodotto una stima ben calibrata della probabilità pre-test dello stato di PTEN.
Nel complesso, la diminuzione dell’espressione della proteina PTEN è correlata con lo stato di mutazione PTEN; la diminuzione dell’espressione della proteina PTEN era correlata con l’aumento del punteggio CC (p <0,001), ma non con i criteri del National Comprehensive Cancer Network (NCCN) (p = 0,11). Per i pazienti pediatrici, abbiamo identificato criteri altamente sensibili per guidare i test di mutazione PTEN, con caratteristiche fenotipiche distinte dall’ambiente adulto. Il nostro modello ha migliorato la sensibilità e il valore predittivo positivo per la mutazione germinale PTEN rispetto ai criteri NCCN 2010 in entrambe le coorti.

Utilizzo del trasferimento dei compiti per aumentare rapidamente i servizi di trattamento dell’HIV: esperienze da Lusaka, Zambia.
L’Organizzazione Mondiale della Sanità sostiene il trasferimento dei compiti, il processo di delega delle funzioni di assistenza clinica da operatori sanitari più specializzati a operatori sanitari meno specializzati, come strategia per raggiungere gli Obiettivi di Sviluppo del Millennio delle Nazioni Unite. Tuttavia, c’è una carenza di letteratura che descrive il trasferimento di compiti nell’Africa subsahariana, dove i servizi per la terapia antiretrovirale (ART) sono aumentati rapidamente di fronte a crisi generalizzate delle risorse umane. Nell’ambito dell’espansione dei servizi ART a Lusaka, Zambia, abbiamo implementato un programma completo di trasferimento delle attività tra i fornitori di servizi sanitari esistenti e i lavoratori della comunità.
La formazione inizia con sessioni didattiche mirate a set di abilità specializzate. Segue un periodo intensivo di tutoraggio pratico, in cui i fornitori vengono associati ai formatori prima di lavorare in modo indipendente. Forniamo una valutazione della qualità continua utilizzando indicatori chiave della qualità dell’assistenza clinica in ogni sito. Le prestazioni del programma vengono riviste trimestralmente con il personale della clinica. Quando vengono identificati i problemi, i membri del personale della clinica progettano e implementano interventi specifici per affrontare aree mirate.
Rabbit Serum Sterile, trace-hemolized (56-84 days old) |
31126-3 |
Pel-Freez |
3L |
EUR 694 |
|
Description: Produced from whole blood collected from young healthy rabbits (New Zealand White or Californian), 6+ months old. Pooled serum from male and female rabbits that are fasted prior to collection. The serum is processed, bottled, and stored at -20°C. Then the serum was thawed, pooled, passed through a 0.22-micron filter, bottled and returned to -20°C. |
Rabbit PLASMA NS K2 EDTA YG LYO (3mL) |
31144L-0 |
Pel-Freez |
10x3ml |
EUR 81.31 |
Antibody analysis - human >30 samples |
8005-3 |
Chondrex |
Custom service |
EUR 113.8 |
Description: Antibody analysis - human >30 samples |
RealScreen Pediatric FSH ELISA Kit |
EL103-096 |
GenDepot |
96T |
EUR 1832 |
Human Plasma Progesterone standard (0 ng/ml) |
1955-P4-00 |
Alpha Diagnostics |
10 ml |
Ask for price |
Haptoglobin, (Phenotype 1-1) Human Plasma |
7536-1 |
Biovision |
|
EUR 321 |
AGEs-BSA |
KH001-A |
Sceti |
|
EUR 870 |
Description: The AGEs-BSA is available in Europe and for worldwide shipping via Gentaur. |
Human IgG-RF stripper/Adsorbent (1 ml, sufficient for stripping 50 samples of 100 ul human serum/plasma) |
RFS-1 |
Alpha Diagnostics |
1 ml |
EUR 103 |
ExoPure? 1.0 micron Immunobeads (Overall Exosome Isolation, plasma, urine, serum, 3 reactions) |
M1039-3 |
Biovision |
|
EUR 436 |
Rabbit Complement 3-4 WK (1-mL) |
31061-0 |
Pel-Freez |
1mL |
EUR 93.28 |
Albumin, Human Plasma |
7546-1 |
Biovision |
|
EUR 240 |
Plasminogen, Human Plasma |
7549-1 |
Biovision |
|
EUR 283 |
Prothrombin, Human Plasma |
7684-1 |
Biovision |
|
EUR 180 |
Ceruloplasmin, Human Plasma |
P1452-1 |
Biovision |
|
EUR 479 |
ExoPure? 0.4 micron Immunobeads (Overall Exosome Isolation, plasma, urine, serum) |
M1038-3 |
Biovision |
|
EUR 436 |
Rabbit PLASMA NS EDTA 500mL |
31141-1 |
Pel-Freez |
500mL |
EUR 261.84 |
Rabbit PLASMA S EDTA 500mL |
31156-1 |
Pel-Freez |
500mL |
EUR 285.76 |
CK PLASMA NS EDTA 500mL |
33141-1 |
Pel-Freez |
500mL |
EUR 184.63 |
CK PLASMA NS HEP 500mL |
33142-1 |
Pel-Freez |
500mL |
EUR 184.63 |
Bovine PLASMA NS EDTA 500mL |
37141-1 |
Pel-Freez |
500mL |
EUR 184.63 |
Bovine PLASMA NS HEP 500mL |
37142-1 |
Pel-Freez |
500mL |
EUR 184.63 |
Pig PLASMA NS EDTA 500mL |
39541-1 |
Pel-Freez |
500mL |
EUR 184.63 |
Pig PLASMA NS HEP 500mL |
39542-1 |
Pel-Freez |
500mL |
EUR 184.63 |
Haptoglobin, Human Plasma (Mixed Type) |
7535-1 |
Biovision |
|
EUR 158 |
Fibrinogen (plasminogen depleted), Human Plasma |
7692-1 |
Biovision |
|
EUR 294 |
Antistreptolysin O (ASO), Human Plasma |
P1453-1 |
Biovision |
|
EUR 207 |
Sheep AGEs ELISA Kit |
ESA0009 |
Abclonal |
96Tests |
EUR 521 |
Mouse AGEs ELISA Kit |
EMA0009 |
Abclonal |
96Tests |
EUR 521 |
Monkey AGEs ELISA Kit |
EMKA0009 |
Abclonal |
96Tests |
EUR 521 |
Porcine AGEs ELISA Kit |
EPA0009 |
Abclonal |
96Tests |
EUR 521 |
Rat AGEs ELISA Kit |
ERA0009 |
Abclonal |
96Tests |
EUR 521 |
Rabbit AGEs ELISA Kit |
ERTA0009 |
Abclonal |
96Tests |
EUR 521 |
Anserini AGEs ELISA Kit |
EAA0009 |
Abclonal |
96Tests |
EUR 521 |
Goat AGEs ELISA Kit |
EGTA0009 |
Abclonal |
96Tests |
EUR 521 |
Chicken AGEs ELISA Kit |
ECKA0009 |
Abclonal |
96Tests |
EUR 521 |
Bovine AGEs ELISA Kit |
EBA0009 |
Abclonal |
96Tests |
EUR 521 |
34011-0 Human Serum Off Clot Single Donor (1mL) |
34011-1 |
Pel-Freez |
1mL |
EUR 68.81 |
Rabbit PLASMA NS W/ HEPARIN 500mL |
31142-1 |
Pel-Freez |
500mL |
EUR 261.84 |
Rabbit PLASMA S NA CIT 500mL |
31155-1 |
Pel-Freez |
500mL |
EUR 285.76 |
CK PLASMA NS S-CIT 500mL |
33140-1 |
Pel-Freez |
500mL |
EUR 184.63 |
Bovine PLASMA NS S-CIT 500mL |
37140-1 |
Pel-Freez |
500mL |
EUR 184.63 |
Pig PLASMA NS S-CIT 500mL |
39540-1 |
Pel-Freez |
500mL |
EUR 184.63 |
Haptoglobin, (Phenotype 2-2) Human Plasma |
7537-1 |
Biovision |
|
EUR 321 |
Alpha 2 HS Glycoprotein, Human Plasma |
7548-1 |
Biovision |
|
EUR 272 |
Thrombin, Active, Bovine Plasma (Technical grade) |
7591-1 |
Biovision |
|
EUR 120 |
Thrombin, Active, Bovine Plasma (High Activity) |
7592-1 |
Biovision |
|
EUR 158 |
Rabbit BRAIN ACETONE POWDER VARISENS (1-g) |
41170-0 |
Pel-Freez |
1g |
EUR 104.15 |
Heart Lysate (14 Days Old) |
1401-14 |
ProSci |
0.1 mg |
EUR 191 |
Description: Heart tissue lysate (14 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT. |
Lung Lysate (14 Days Old) |
1402-14 |
ProSci |
0.1 mg |
EUR 191 |
Description: Lung tissue lysate (14 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT. |
Lung Lysate (7 Days Old) |
1402-7 |
ProSci |
0.1 mg |
EUR 191 |
Description: Lung tissue lysate (7 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT. |
Brain Lysate (14 Days Old) |
1403-14 |
ProSci |
0.1 mg |
EUR 191 |
Description: Brain tissue lysate (14 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT. |
Brain Lysate (7 Days Old) |
1403-7 |
ProSci |
0.1 mg |
EUR 191 |
Description: Brain tissue lysate (7 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT. |
Liver Lysate (14 Days Old) |
1404-14 |
ProSci |
0.1 mg |
EUR 191 |
Description: Liver tissue lysate (14 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT. |
Liver Lysate (7 Days Old) |
1404-7 |
ProSci |
0.1 mg |
EUR 191 |
Description: Liver tissue lysate (7 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT. |
Kidney Lysate (14 Days Old) |
1405-14 |
ProSci |
0.1 mg |
EUR 191 |
Description: Kidney tissue lysate (14 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT. |
Kidney Lysate (7 Days Old) |
1405-7 |
ProSci |
0.1 mg |
EUR 191 |
Description: Kidney tissue lysate (7 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT. |
Spleen Lysate (14 Days Old) |
1406-14 |
ProSci |
0.1 mg |
EUR 191 |
Description: Spleen tissue lysate (14 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT. |
Spleen Lysate (7 Days Old) |
1406-7 |
ProSci |
0.1 mg |
EUR 191 |
Description: Spleen tissue lysate (7 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT. |
Thymus Lysate (14 Days Old) |
1409-14 |
ProSci |
0.1 mg |
EUR 191 |
Description: Thymus tissue lysate (14 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT. |
Thymus Lysate (7 Days Old) |
1409-7 |
ProSci |
0.1 mg |
EUR 191 |
Description: Thymus tissue lysate (7 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT. |
Stomach Lysate (14 Day Old) |
1415-14 |
ProSci |
0.1 mg |
EUR 191 |
Description: Stomach tissue lysate (14 Day Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT. |
Stomach Lysate (7 Day Old) |
1415-7 |
ProSci |
0.1 mg |
EUR 191 |
Description: Stomach tissue lysate (7 Day Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT. |
Skin Lysate (14 Days Old) |
1419-14 |
ProSci |
0.1 mg |
EUR 191 |
Description: Skin tissue lysate (14 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT. |
Skin Lysate (7 Days Old) |
1419-7 |
ProSci |
0.1 mg |
EUR 191 |
Description: Skin tissue lysate (7 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT. |
Eye Lysate (14 Days Old) |
1420-14 |
ProSci |
0.1 mg |
EUR 191 |
Description: Eye tissue lysate (14 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT. |
Eye Lysate (7 Days Old) |
1420-7 |
ProSci |
0.1 mg |
EUR 191 |
Description: Eye tissue lysate (7 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT. |
Yersinia Enterocolitica 0:3 Protein |
abx061492-01ml |
Abbexa |
0.1 ml |
EUR 551 |
|
Rabbit PLASMA NS NA CIT Y 500mL |
31140-1 |
Pel-Freez |
500mL |
EUR 261.84 |
Rabbit PLASMA NS K2 EDTA Y 500mL |
31144-1 |
Pel-Freez |
500mL |
EUR 261.84 |
Rabbit PLASMA NS K3 EDTA YG 500mL |
31145-1 |
Pel-Freez |
500mL |
EUR 233.56 |
Guinea Pig AGEs ELISA Kit |
EGA0009 |
Abclonal |
96Tests |
EUR 521 |
Mouse Aquaporin 0(AQP-0)ELISA Kit |
GA-E0524MS-48T |
GenAsia Biotech |
48T |
EUR 336 |
Mouse Aquaporin 0(AQP-0)ELISA Kit |
GA-E0524MS-96T |
GenAsia Biotech |
96T |
EUR 534 |
Human Aquaporin 0(AQP-0)ELISA Kit |
GA-E1301HM-48T |
GenAsia Biotech |
48T |
EUR 289 |
Human Aquaporin 0(AQP-0)ELISA Kit |
GA-E1301HM-96T |
GenAsia Biotech |
96T |
EUR 466 |
Human Aquaporin 0,AQP-0 ELISA Kit |
201-12-1285 |
SunredBio |
96 tests |
EUR 440 |
|
Description: A quantitative ELISA kit for measuring Human in samples from biological fluids. |
Rat Aquaporin 0,AQP-0 ELISA Kit |
CN-01885R1 |
ChemNorm |
96T |
EUR 471 |
Rat Aquaporin 0,AQP-0 ELISA Kit |
CN-01885R2 |
ChemNorm |
48T |
EUR 322 |
Mouse Aquaporin 0,AQP-0 ELISA Kit |
CN-02762M1 |
ChemNorm |
96T |
EUR 464 |
Mouse Aquaporin 0,AQP-0 ELISA Kit |
CN-02762M2 |
ChemNorm |
48T |
EUR 313 |
Human Aquaporin 0,AQP-0 ELISA Kit |
CN-04417H1 |
ChemNorm |
96T |
EUR 464 |
Dal 2005 al 2007, abbiamo formato 516 operatori sanitari nel trattamento dell’HIV negli adulti; 270 nel trattamento dell’HIV pediatrico; 341 in consulenza per l’adesione; 91 in un corso di “triage” per infermiere specializzato e 93 in un programma intensivo di tutoraggio clinico. La valutazione della qualità in corso ha dimostrato un miglioramento tra gli indicatori di qualità dell’assistenza clinica, nonostante i volumi di pazienti in rapida crescita. La nostra strategia di spostamento delle attività è stata progettata per soddisfare le attuali esigenze degli operatori sanitari e per sostenere le attività di scale-up ART. Sebbene questo approccio abbia avuto successo, sono urgentemente necessarie anche soluzioni a lungo termine alla crisi delle risorse umane per espandere il numero di fornitori e rallentare la migrazione del personale fuori dalla regione.